Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Is there data to support the upfront use of encorafenib and cetuximab in metastatic BRAF V600E-mutated right-sided colon cancer?
Answer from: Medical Oncologist at Academic Institution
There is an ongoing trial (BREAKWATER) that will answer this but not yet.
Sign in or Register to read more
22108
Related Questions
How would you treat an older patient with multiple co-morbidities and borderline performance status with resectable esophageal cancer in light of ESOPEC trial?
How would you treat a patient with a synchronous T1N2 non-small cell lung cancer and a T3N1 mid-rectal adenocarcinoma (MMR intact)?
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
Is there a standard of care for management of localized DNA mismatch repair deficient esophagus cancer?
For T3N0 rectosigmoid tumors who get surgery upfront, what is your preferred adjuvant therapy?
How would you approach a stage II colon cancer with negative ctDNA but markedly elevated CEA level post-colectomy?
How would you manage a patient with metastatic HCC on atezolizumab/bevacizumab who requires holding bevacizumab due to persistent proteinuria >2g?
Would you offer neoadjuvant radiation therapy with concurrent chemotherapy for a T4 rectal carcinoma with an associated rectovesical fistula?
After R1 resection of a locally advanced, node-positive neuroendocrine tumor of the terminal ilium, would you offer adjuvant radiation therapy?
What is your preferred third-line therapy for metastatic colon cancer, RAS-WT, MSS, low TMB with no targetable alterations?